Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 56 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Tissue Reaction Clear all

Conditions: Allergic Skin Reaction
Interventions: Hyaluronidase, Histamine, Saline; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 253 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 5
States / cities: Eugene, Oregon • Lake Oswego, Oregon • Portland, Oregon + 2 more

Conditions: Dermatitis, Photoallergic
Interventions: Butenafine HCl 1% (BAY1896425) - Induction Phase, Butenafine HCl 1% (BAY1896425) - Challenge Phase; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Fairfield, New Jersey

Conditions: Central Nervous System/Leptomeningeal Neoplasms
Interventions: 131I-omburtamab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteosarcoma
Interventions: Blood draw; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 3 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Hand-foot Skin Reaction, Rash
Interventions: urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, bland emollient cream (Udderly smooth® Udder Cream); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acne Vulgaris
Interventions: Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Doxorubicin Adverse Reaction, Cardiomyopathies, Secondary, Breast Cancer
Interventions: Not listed
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • Oak Park, Illinois

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Staphylococcus Aureus, Staphylococcal Skin Infections, Bacteremia
Interventions: Not listed
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oral Lichen Planus, Oral Lichenoid Reaction
Interventions: dexamethasone oral rinse; Drug
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overweight
Interventions: Weight Control; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Irvine, California

Conditions: Injection Site Irritation, Injection Site Bruising, Injection Site Discomfort, Benzoic Acid Adverse Reaction, Anesthesia, Local
Interventions: Sodium Chloride 0.9% Inj, Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML); Drug
Lead sponsor: Jeffrey Alan Klein, MD; Industry
Eligibility: 16 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Juan Capistrano, California

Conditions: CVI - Common Variable Immunodeficiency
Interventions: C1-esterase inhibitor [recombinant] (C1-INH-R); Biological
Lead sponsor: IMMUNOe Research Centers; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Centennial, Colorado

Conditions: Drug Hypersensitivity
Interventions: Vitrase; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Davis, California

Conditions: Oral Lichen Planus, Oral Lichenoid Mucositis, Oral Lichenoid Reaction
Interventions: Ibuprofen suspension 5mg/100ml, Placebos; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Dermal Hypersensitivity Reaction
Interventions: Dupilumab; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anaphylaxis, Hypotension, Bronchospasm, Angioedema
Interventions: Epinephrine, Omalizumab (Xolair), Placebos; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dystonic Disorders, Healthy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adverse Local Tissue Reaction, Total Hip Arthroplasty
Interventions: ASR-XL Metal-on-Metal; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: Not listed
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Fort Collins, Colorado • Glenview, Illinois • Rockford, Illinois + 4 more

Conditions: Complications; Arthroplasty, Complications; Arthroplasty, Mechanical
Interventions: Not listed
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 21 Years to 95 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Subject, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Biospecimen Collection, Functional Magnetic Resonance Imaging, Questionnaire Administration; Procedure · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Drug Hypersensitivity
Interventions: Vitrase; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Davis, California

Conditions: Photoallergy
Interventions: Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation, Induction: Applications of MC2-01 vehicle, no irradiation, Challenge: Application of MC2-01 Cream, irradiation, Challenge: Application of MC2-01 Cream, no irradiation, Challenge: Applications of MC2-01 vehicle, irradiation, Challenge: Applications of MC2-01 vehicle, no irradiation, Challenge: Control, irradiation; Drug
Lead sponsor: MC2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Normal-weight Obesity, BMI, Stress
Interventions: high-fat meal, Stress; Other
Lead sponsor: Ball State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Muncie, Indiana

Search by objective public record fields.

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction

Sorafenib-induced Hand- Foot Skin Reaction Treatment

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor

Effect of Transcranial Magnetic Stimulation on Free Will

Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections

Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus

The Use of Diffuse Optical Spectroscopy to Characterize in Response to Weight-Loss Intervention

Comparison of Subcutaneous Injection of Normal Saline and Bacteriostatic Saline

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.

The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Surround Inhibition in Patients With Dystonia

ASR-XL Metal-on-Metal 522 Post-Market Surveillance Study

Using MRI To Detect Soft Tissue Reactions And Implant Integration As Related To Implant Modularity

Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream

Effects of Body Composition on Vascular Health in Females With a Healthy Body Weight